- Home
- PAVM vs RDHL Comparison
PAVM vs RDHL Comparison
Compare PAVM & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- RDHL
- Stock Information
- Founded
- PAVM 2014
- RDHL 2009
- Country
- PAVM United States
- RDHL Israel
- Employees
- PAVM N/A
- RDHL N/A
- Industry
- PAVM Medical/Dental Instruments
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- RDHL Health Care
- Exchange
- PAVM Nasdaq
- RDHL Nasdaq
- Market Cap
- PAVM 7.2M
- RDHL 8.2M
- IPO Year
- PAVM 2016
- RDHL N/A
- Fundamental
- Price
- PAVM $0.65
- RDHL $5.82
- Analyst Decision
- PAVM Strong Buy
- RDHL
- Analyst Count
- PAVM 1
- RDHL 0
- Target Price
- PAVM $19.00
- RDHL N/A
- AVG Volume (30 Days)
- PAVM 210.8K
- RDHL 10.9K
- Earning Date
- PAVM 03-25-2025
- RDHL 08-29-2024
- Dividend Yield
- PAVM N/A
- RDHL N/A
- EPS Growth
- PAVM N/A
- RDHL N/A
- EPS
- PAVM 0.53
- RDHL N/A
- Revenue
- PAVM $4,034,000.00
- RDHL $3,707,000.00
- Revenue This Year
- PAVM $52.90
- RDHL $224.90
- Revenue Next Year
- PAVM $248.84
- RDHL $82.69
- P/E Ratio
- PAVM $1.23
- RDHL N/A
- Revenue Growth
- PAVM 166.27
- RDHL N/A
- 52 Week Low
- PAVM $0.57
- RDHL $5.41
- 52 Week High
- PAVM $3.50
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- PAVM 45.41
- RDHL 39.72
- Support Level
- PAVM $0.62
- RDHL $5.76
- Resistance Level
- PAVM $0.70
- RDHL $6.45
- Average True Range (ATR)
- PAVM 0.05
- RDHL 0.32
- MACD
- PAVM 0.01
- RDHL 0.01
- Stochastic Oscillator
- PAVM 61.20
- RDHL 20.33
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.